Comorbidities defined by the Charlson comorbidity index (CCI) and body mass index (BMI) are significantly associated with outcome in patients who receive continuous treatment with tyrosine kinase inhibitors. We evaluated the impact of CCI and BMI on responses, drug-related toxicities, and outcome in a cohort of 402 patients with myelofibrosis (MF) treated with ruxolitinib in 23 European Hematology Centers. Comorbidities were evaluable in all 402 patients. A higher (≥ 3) CCI did not correlate with a lower spleen reduction at any time (p = 0.68) or symptoms' response (p = 0.11), but influenced the onset of anemia during the first 3 months of treatment and later (p = 0.02 and p = 0.03, respectively) in patients without anemia baseline. BMI was evaluable in 380 patients and did not correlate with differences in spleen and symptoms response (p = 0.57 and p = 0.49, respectively). A higher CCI and a lower BMI correlated also with a reduced overall survival (p < 0.001 and p = 0.02, respectively). The achievement of a spleen response at 6 months could counterbalance the negative impact of comorbidities, while patients who were underweight when starting ruxolitinib and did not achieve a spleen response at 6 months were projected to the worse outcome. In MF patients treated with ruxolitinib, BMI and comorbidities did not influence the achievement of spleen/symptom responses, but they contributed to the early identification of patients who deserve a strict monitoring during treatment.
Introduction
In the last few years, several reports have demonstrated the impact of comorbidities on survival in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). Indeed, the German group has shown in a large CML series that a higher Charlson comorbidity index (CCI) at baseline significantly correlated with reduced survival regardless of the response achieved during imatinib therapy [1] . In addition, comorbidities predicted worse prognosis in patients with primary myelofibrosis [2] . Together with comorbidities, also body mass index may be relevant in prognosis of patients with cancer [3] . According to WHO criteria, people may be stratified into four categories: underweight (BMI < 18.5), normal weight (18.5-25) , overweight (25) (26) (27) (28) (29) (30) , and obese (≥ 30) [4] . Increased BMI was associated with delayed cytogenetic and major molecular responses to imatinib in CML patients [5] .
Ruxolitinib is the first JAK1/JAK2 inhibitor approved for the treatment of splenomegaly and symptoms associated with myelofibrosis (MF). The prospective COMFORT 1 and COMFORT 2 studies randomized MF patients to receive either ruxolitinib or placebo and best available therapies, respectively, demonstrating the superiority of ruxolitinib in terms of reduction of splenomegaly, amelioration of symptoms and improvement of quality of life [6, 7] . A longer follow-up of the COMFORT studies also documented a survival advantage of patients treated with ruxolitinib compared to placebo and best available treatment [8, 9] . The impact of comorbidities has not been detailed systematically in the COMFORT studies or the JUMP trial [10] and only 13% of patients assigned to ruxolitinib showed a performance score ECOG > 2 in the COMFORT-II trial [8] . Therefore, a clear benefit of ruxolitinib for patients with impaired clinical conditions has never been demonstrated and the European LeukemiaNet/SIE panel has suggested to avoid the drug in frail patients [11] .
Here, we retrospectively assessed the impact of comorbidities and BMI on clinical responses, overall survival and maintenance of ruxolitinib dose in a large cohort of MF patients.
Methods
An electronic database was established to collect clinical, molecular and laboratory data on MF patients treated with ruxolitinib in 23 European Hematology Centers as previously described [12] . Between June 2011 and November 2016, data on 462 consecutive MF patients were retrospectively collected. Data cut-off was January 2018. Two-hundred thirty-four patients were enrolled in the J U M P t r i a l ( C l i n i c a l T r i a l s . g o v I d e n t i f i e r s : NCT01493414) and 168 patients received ruxolitinib as compassionate or commercial use/off-study according to the standard clinical practice.
A diagnosis of primary myelofibrosis (PMF) and postessential thrombocythemia/polycythemia vera myelofibrosis (post-ET/post-PV MF) was made according to the WHO 2008 [13] or the International Working Group on Myelofibrosis Research and Treatment (IWG-MRT) criteria [14] . Bone marrow fibrosis was graded according to the European Consensus Grading System [15] . Evolution into blast phase was based on the WHO classification [16] . Molecular tests for detection of JAK2, MPL, and CALR mutations and cytogenetic analysis were carried out as described elsewhere [17] . Ruxolitinib was administrated according to the prescribing information. Spleen and symptoms' responses have been defined according to the International Working Group on Myelofibrosis Research and Treatment/European Leukemia Net (IWG-MRT/ELN) criteria [18] . Symptoms' response was assessed by changes in the Myeloproliferative Neoplasm Symptom Assessment Form total symptoms score (TSS) [19] .
Anemia and thrombocytopenia were graded according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) v 4.0 (https://www.eortc.be/ s e r v i c e s / d o c / c t c / C T C A E _ 4 . 0 3 _ 2 0 1 0 -0 6 -1 4 _ QuickReference_5x7.pdf). Drug-induced anemia and thrombocytopenia were defined as increasing in anemia/ thrombocytopenia grade with respect to baseline levels. Patients that were transfusion-dependent before the start of ruxolitinib therapy were not evaluable for subsequent anemia.
BMI was calculated at the time of start of ruxolitinib treatment. BMI was defined as the individual's body weight in kilogram divided by the square of his/her height, which produces a unit of measure of kg/m2.
Comorbidities were recorded at the time of the start of ruxolitinib and classified according to the CCI [20] . Comorbidities were evaluated at baseline, before ruxolitinib treatment, by the medical staff. All information about concomitant diseases and drug usage were recorded in each case history and thereafter used for this retrospective evaluation. As reported, CCI is a list of 19 comorbid conditions: each condition has a weight assigned from 1 to 6, which is derived from the relative risk estimates of a proportional hazard regression model using clinical data. For the condition Bleukemia-malignancy,^2 points were assigned only in case of occurrence of an additional malignancy to MF prior to ruxolitinib start.
The study was approved by the Institutional Review Board of each Institution and was conducted according to the Helsinki declaration. Clinical and laboratory parameters were evaluated both at diagnosis and at the start of ruxolitinib.
Statistical analysis
Categorical variables have been summarized by their median and range or mean and standard deviation, according to the statistical analysis performed, and categorical variables by count and relative frequency (%) of each category. Comparisons of continuous variables between groups of patients were carried out using the Wilcoxon-Mann-Whitney rank-sum test or the Student's t test, when compared between two groups, or the ANOVA or Kruskal-Wallis tests, when compared between 3 groups, and the association between categorical variables (two-way tables) was tested by the Fisher's exact test or χ2, as appropriate. Overall survivals (OS) were performed using Kaplan-Meier analysis, from the start of ruxolitinib to death or last contact, and compared by the logrank test, also used for pairwise comparisons when considering multiple categories. Progression-free survival (PFS) took into account death from any cause and progression to blast phase. When calculating OS and PFS from the start of ruxolitinib, the survival analysis was adjusted for left truncation (Bdelayed entry^). When adjusting for the Dynamic International Prognostic Score System (DIPSS) category at treatment, OS and PFS were calculated using the Cox proportional hazards multivariate regression model. The cumulative incidence of infections was calculated considering death as competing risk, according to the model of Fine and Gray. All reported p values are two-sided, and p values < 0.05 were considered statistically significant. All statistical analyses were performed with STATA15.
Results

Study cohort
Between June 2011 and April 2016, 462 MF patients were treated with ruxolitinib in the participating Centers. Of the whole cohort, a total of 402 patients were evaluable for CCI and were included in this study. Three hundred eighty patients (94.5%) had also data on BMI at the start of treatment.
At ruxolitinib start, the median age was 64 years (range 39-89) with a male prevalence (52.4% The most common comorbidities were peripheral vascular disease (14%), previous solid tumor (13.5%), diabetes (10%), and liver disease (9.6%). Compared to patients with CCI = 0, patients with CCI 1-2 and ≥ 3 were more frequently in the intermediate-2 DIPPS category (p = 0.03), with a hemoglobin level < 10 g/dl (33.8% in CCI = 0, 43.7% in CCI = 1-2 and 56.6% in CCI ≥ 3, p = 0.005) and transfusion dependence (20% vs 28.1% and 34.2%, p = 0.04).
Overall, 12 patients (3.2%) had a BMI < 18.5, 225 (59.2%) were normal weighted, 123 (32.4%) a BMI between 25 and 30 while 20 patients (5.2%) were obese. Median BMI was 23.9 (range, 15.5-33.3). Overweight patients (BMI ≥ 25) were more frequently males (p = 0.001), belonged more frequently to the intermediate-1 DIPSS category, and had less anemia: a hemoglobin value < 10 g/dl at presentation was found in 45.0% of patients with a BMI < 25 and 33.8% with a BMI ≥ 25 (p = 0.03). The burden of symptoms in terms of presence of constitutional symptoms and average 10-item TSS was not significantly influenced by CCI and BMI.
Impact of comorbidities and BMI on response to ruxolitinib
Overall, 354 patients were evaluable for spleen response and 379 for symptoms response according to the IWG-MRT criteria. A total of 138 (39.0%) and 309 (81.5%) patients achieved a spleen or a symptom response at any time during therapy, respectively. More specifically, at 3 and 6 months, 100 (28.2%) and 122 (37.9%) out of 354 and 322 evaluable patients were in spleen response, while 277 (73%) and 263 (82.1%) out of 379 and 320 evaluable patients were in symptoms response, respectively.
By stratifying patients into 3 categories with different CCI (CCI = 0, CCI 1-2, and CCI ≥ 3), a higher CCI did not correlate with a lower spleen response at any time (achieved by 37.6%, 38.5%, and 43.7% of patients with CCI = 0, 1-2, and ≥ 3, respectively, p = 0.68), or symptoms response at any time (achieved by 77.3%, 85.9%, and 84.9% in patients with CCI = 0, 1-2, and ≥ 3, respectively, p = 0.11). The rates of spleen and symptoms responses were also comparable at 3 and 6 months across the three CCI groups.
Patients were also subdivided into three categories according to a BMI below the first quartile (< 21.9, n.96), a BMI between 21.9 and 24.9 (normal weight, n. 142) and BMI ≥ 25 (overweight, n. 142). BMI categories were not significantly associated with differences in spleen response (achieved by 40.7%, 35.2%, and 41.3% of patients with a BMI < 21.9, 21-24.9, and ≥ 25, respectively, p = 0.57), or symptom response (achieved by 79.3%, 79.7%, and 84.6% of patients, respectively, p = 0.49) at any time. Also, the rates of spleen and symptoms responses were comparable across the three groups of patients both at 3 (p = 0.85 and p = 0.32) and 6 months (p = 0.73 and p = 0.63).
Average starting and overall ruxolitinib doses were comparable across both CCI (p = 0.78) and BMI (p = 0.37) groups.
Impact of comorbidities and BMI on toxicity to ruxolitinib
Overall, 229 (75.6%) of 303 evaluable patients, who were not transfusion-dependent at the start of ruxolitinib, experienced an increase in anemia grade; comorbidities and BMI did not influence the increase of ruxolitinib-related anemia grade over time (Table 2) . However, the incidence of ruxolitinib-induced grade ≥ 2 anemia in the 132 patients that started ruxolitinib without anemia (i.e., with a hemoglobin level ≥ 12 g/dl in absence of transfusion requirement) was significantly higher in patients with CCI ≥ 3 ( Table 3) .
Thrombocytopenia of any grade at any time was observed in 204 of the 394 evaluable patients (grade 3-4 in 10.8%) and was never associated with CCI and BMI (Tables 2 and 3) .
Infections grade ≥ 2 occurred in 120 (29.9%) patients, after a median time form ruxolitinib start of 5.9 months (range, 1-60.9). More specifically, infections were pneumonia in 25.8% of cases (grade 2 in 11 patients, grade 3 in 14 and grade 4-5 in 6), bronchitis in 15% of cases (grade 2 in 16 patient and grade 3 in two), gastrointestinal infections in 8.3% of cases (grade 2 in 4 patients, grade 3 in 5 and grade 4 in 1), urinary tract infections in 8.3% of cases (grade 2 in 9 patients and grade 3 in 1), herpesvirus infections in 10% of cases (grade-2 Herpes Simplex infections in 6 patients and grade-2 and grade-3 Herpes zoster infections in 5 and 1 patient, respectively), cutaneous infections in 5.8% of cases (grade-2 in 6 patients and grade-3 in 1), upper airways infections in 7.7% of cases (grade-2 in 8 patients and grade-3 in 1), fever in 15% of cases (grade-2 in 13 patients and grade 3-4 in 5), and sepsis in 1.7% of cases (one grade-3 and grade-4 in 1). In addition, grade-2 tuberculosis, grade-2 eye infection, and grade-2 renal infection were recorded in 1 patient each. After adjustment for risk of death, the cumulative incidence of infections during treatment was not influenced by CCI and BMI stratification (p = 0.27 and p = 0.95, respectively).
Impact of comorbidities and BMI on outcome
Overall, 17 (4.2%). patients were submitted to allogeneic stem cell transplant after ruxolitinib failure. These patients were censored at the time of transplant for survival analysis.
Accounting for left-truncation, overall and progressionfree survival differed significantly between the different CCI groups (p = 0.01 and 0.04, respectively). CCI maintained its prognostic value even when adjusted for DIPSS (p < 0.001 and 0.001, respectively) (Fig. 1a, b) . As in the CCI stratification, also the BMI correlated with DIPSS-adjusted OS (p = 0.003) and PFS (p = 0.003) (Fig. 1c, d ) after left truncation.
A landmark Kaplan-Meier survival analysis, from 6 months from ruxolitinib start onwards, was performed to compare patients according to response to ruxolitinib at 6 months and CCI. Log-rank tests showed that patients with an IWG-MRTdefined spleen response and a CCI < 3 had the best OS compared to all the other categories (Fig. 2a) . Notably, in patients with a comparable CCI below 3, the achievement of a spleen response at 6 months significantly improved OS. Log-rank tests also showed that patients who did not obtain a response and with a BMI < 21.9 had the worse outcome (Fig. 2b) . Here, achieving a spleen response could significantly improve the outcome of patients starting treatment while underweight.
Discussion
Comorbidities influence the prognosis of patients affected by cancers and impact on treatment decisions [2, [21] [22] [23] . While an accurate evaluation of comorbidities and nutritional status is now part of the routine baseline assessment of CML patients, these parameters have never been investigated in depth in patients with MF treated with ruxolitinib.
Our analysis in a large series of MF patients homogeneously treated with ruxolitinib in the clinical practice showed that baseline comorbidities, such as in other diseases, have a role in predicting survival, but do not influence the probability of achieving a spleen response or the control of inflammationrelated symptoms. Also, patients with a lower burden of comorbidities at baseline who achieve a spleen response seem to have a better prognosis compared to non-responders with a similar CCI. This cut-off of CCI (< 3) could be of help to identify patients who may deserve a treatment with ruxolitinib, considering that a spleen response with a limited burden of comorbid conditions may result in the best outcome.
We found that patients with an increased burden of comorbidities present more frequently anemia at baseline and during the Log-rank test for overall difference between all the Kaplan-Meier curves, considering data from the 6-month landmark onwards. Pairwise Log-rank tests between the curves confirmed which categories significantly differ from the others, majorly impacting on the overall difference. Specifically, a patients with spleen response at 6 months and with lower CCI had a significantly improved overall survival compared to nonresponding patients with a lower CCI (p = 0.02), to responding patients with a higher CCI (p = 0.008), and to non-responding patients with a higher CCI (p = 0.007), and b patients with no spleen response at 6 months and a lower BMI had a significantly worse overall survival compared to non-responding patients with a high BMI (p = 0.001), responding patients with higher BMI (p < 0.001), and responding patients with a lower BMI (p = 0.04). In both analyses, the other three categories of patients were statistically comparable therapy: physicians must be aware that a strict weekly monitoring should be carried out to check the onset of transfusiondependence if CCI is higher than 3 at baseline. Unlike in CML, BMI did not impact significantly on the response rates or on the onset of toxicities in MF patients treated with ruxolitinib. On the contrary, the drug is likely to ameliorate MF-related cachexia resulting in improved survival through the improvement of cytokine levels. The achievement of a spleen response in patients with initial diseaserelated cachexia correlated with an improvement of OS compared to patients with a similar BMI but who did not achieve such a response. Therefore, MF-related cachexia should not prevent per se the choice of starting treatment with ruxolitinib.
Our group has recently proposed a comprehensive assessment for frail patients with Philadelphia-positive and Philadelphia-negative chronic myeloproliferative neoplasms who need to be treated with TKIs: BMI evaluation was included together with performance status, instrumental activities of daily living, CCI and short physical performance battery (SPPB) [24] . More recently, an innovative Bcachexia index^was proposed in order to provide a more objective quantification of constitutional symptoms in PMF [25] . This score takes two widely available laboratory tests into account, serum albumin and cholesterol levels, which were found to correlate with survival regardless of IPSS/DIPSS category. Overall, these parameters may reflect the hypercatabolic/ cachectic state of the disease and confirm the role of the nutritional status on outcome [25] .
In conclusion, comorbidities and BMI do not seem to be a contraindication for ruxolitinib therapy in MF patients, but may contribute to better define the profile of patients who deserve a strict monitoring during treatment.
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